Press Releases

India’s Bharat Biotech submits data on COVID-19 drug trial in children

10/11/2021

Excerpt from the Press Release: BENGALURU, Oct 6 (Reuters) – Bharat Biotech said on Wednesday it had submitted data from its COVID-19 vaccine trial in children aged 2 to 18 years to India’s drug regulator, becoming the country’s first company to have tested its shot in very young children. The South Asian country is turning…

Read More

Boston Scientific Announces Agreement to Acquire Baylis Medical Company Inc.

10/11/2021

Acquisition to add new left heart access platforms to electrophysiology and structural heart portfolios Excerpt from the Press Release: MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to…

Read More

Protecting cancer patients from COVID-19: world-first clinical trial tests a novel immune-boosting strategy

10/11/2021

Excerpt from the Press Release In the race to find new ways to prevent and treat COVID-19, OICR-supported researchers have launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients. The trial involves IMM-101, a preparation of safe, heat-killed bacteria that broadly stimulates the…

Read More

Kinetic River Corp. Receives First Japanese Patent for Time-Resolved Flow Cytometry

10/08/2021

This issuance expands global protection for Kinetic River’s technologies aimed at expanding the power of flow cytometry Excerpt from the Press Release: MOUNTAIN VIEW, Calif., Oct. 1, 2021 /PRNewswire/ — Kinetic River Corp., a leader in custom flow cytometry instrumentation, announced today having been issued a patent from the Japanese Patent Office covering its innovative technologies…

Read More

Amolyt Pharma Announces Positive Data from Phase 1 Trial of AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual Meeting

10/08/2021

Excerpt from the Press Release: LYON, France and CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) — Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced positive results from its Phase 1 clinical trial of AZP-3601, a potential treatment for hypoparathyroidism, at the American Society for Bone…

Read More

Inflammasome Therapeutics’ Kamuvudines Continue to Show Promise for Future Treatment – and Potentially a Cure – for Blindness in Seniors

10/07/2021

New research published today in Science Advances describes precise mechanism of how Alu reverse transcription occurs from RNA to cDNA, and its subsequent triggering of inflammasome activation and consequent cell death in Geographic Atrophy (GA) – the most severe form of dry age-related macular degeneration. Research shows Alu RNA/cDNA reverse transcription confined to rim of…

Read More

Edison Oncology and Apollomics Inc. Announce Treatment of First Patient For EO1001 (APL-122) in a Phase I/IIa Clinical Trial

10/07/2021

Excerpt from the Press Release: MENLO PARK, Calif., FOSTER CITY, Calif. and HANGZHOU, China, Sept. 30, 2021 (GLOBE NEWSWIRE) — Edison Oncology Holding Corp. (“Edison Oncology”), a company established to develop new therapies targeting the fight against cancer, and Apollomics Inc. (“Apollomics”), an innovative biopharmaceutical company committed to the discovery and development of mono- and…

Read More

Innovent Announces the First Patient Dosed in the Phase I/II Study of IBI351 (KRAS G12C inhibitor) in Patients with Advanced Malignant Tumors

10/07/2021

Excerpt from the Press Release: SAN FRANCISCO and SUZHOU, China, Sept. 29, 2021 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced a phase I/II clinical study of KRAS G12C inhibitor IBI351…

Read More

Phil Announces Partnership with Impel NeuroPharma in Support of Trudhesa™ (dihydroergotamine mesylate) Nasal Spray for the Acute Treatment of Migraine

10/06/2021

Excerpt from the Press Release: SAN FRANCISCO, Sept. 29, 2021 /PRNewswire/ — Phil, Inc. announces partnership with Impel NeuroPharma, Inc. (NASDAQ: IMPL) in support of Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) to provide technology-powered patient support and distribution services through Phil’s proprietary workflow to enhance the patient’s access to therapy. Trudhesa is indicated for the acute treatment of…

Read More

OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)

10/06/2021

Decision taken to move the highest dose of THR-149 (0.13mg) into Part B of the study based on favorable safety profile and positive efficacy data Oxurion is moving into Part B of study evaluating THR-149 against aflibercept THR-149 is a potent plasma kallikrein inhibitor for the treatment of the 40-50% of DME patients who respond…

Read More